Semiparametric inference for surrogate endpoints with bivariate censored data
- PMID: 17651457
- DOI: 10.1111/j.1541-0420.2007.00834.x
Semiparametric inference for surrogate endpoints with bivariate censored data
Abstract
Considerable attention has been recently paid to the use of surrogate endpoints in clinical research. We deal with the situation where the two endpoints are both right censored. While proportional hazards analyses are typically used for this setting, their use leads to several complications. In this article, we propose the use of the accelerated failure time model for analysis of surrogate endpoints. Based on the model, we then describe estimation and inference procedures for several measures of surrogacy. A complication is that potentially both the independent and dependent variable are subject to censoring. We adapt the Theil-Sen estimator to this problem, develop the associated asymptotic results, and propose a novel resampling-based technique for calculating the variances of the proposed estimators. The finite-sample properties of the estimation methodology are assessed using simulation studies, and the proposed procedures are applied to data from an acute myelogenous leukemia clinical trial.
Similar articles
-
Proportional hazards regression for cancer studies.Biometrics. 2008 Mar;64(1):141-8. doi: 10.1111/j.1541-0420.2007.00830.x. Epub 2007 Jun 15. Biometrics. 2008. PMID: 17573863
-
Regression analysis of panel count data with dependent observation times.Biometrics. 2007 Dec;63(4):1053-9. doi: 10.1111/j.1541-0420.2007.00808.x. Biometrics. 2007. PMID: 18078478
-
Semiparametric analysis of survival data with left truncation and dependent right censoring.Biometrics. 2005 Jun;61(2):567-75. doi: 10.1111/j.1541-0420.2005.00335.x. Biometrics. 2005. PMID: 16011706
-
The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.Stat Methods Med Res. 2008 Jun;17(3):303-40. doi: 10.1177/0962280207082719. Epub 2007 Oct 9. Stat Methods Med Res. 2008. PMID: 17925313 Review.
-
Statistical evaluation of biomarkers as surrogate endpoints: a literature review.Stat Med. 2006 Jan 30;25(2):183-203. doi: 10.1002/sim.2319. Stat Med. 2006. PMID: 16252272 Review.
Cited by
-
Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker.Biometrika. 2020 Mar;107(1):107-122. doi: 10.1093/biomet/asz065. Epub 2019 Dec 24. Biometrika. 2020. PMID: 32587413 Free PMC article.
-
Allometric scaling patterns among the human coronary artery tree, myocardial mass, and coronary artery flow.Physiol Rep. 2020 Jul;8(14):e14514. doi: 10.14814/phy2.14514. Physiol Rep. 2020. PMID: 32725793 Free PMC article.
-
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling.Biometrics. 2012 Mar;68(1):226-32. doi: 10.1111/j.1541-0420.2011.01633.x. Epub 2011 Jun 13. Biometrics. 2012. PMID: 21668903 Free PMC article.
-
On assessing surrogacy in a single trial setting using a semicompeting risks paradigm.Biometrics. 2009 Jun;65(2):521-9. doi: 10.1111/j.1541-0420.2008.01109.x. Biometrics. 2009. PMID: 18759839 Free PMC article.
-
Estimation of the proportion of treatment effect explained by a high-dimensional surrogate.Stat Med. 2022 May 30;41(12):2227-2246. doi: 10.1002/sim.9352. Epub 2022 Feb 21. Stat Med. 2022. PMID: 35189671 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources